review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1052072204 |
P356 | DOI | 10.1007/S00393-005-0721-9 |
P698 | PubMed publication ID | 15868333 |
P2093 | author name string | M Kayser | |
L Unger | |||
K Manger | |||
H Nüsslein | |||
M Enderlein | |||
P2860 | cites work | Factors associated with coronary artery calcification in young female patients with SLE. | Q33188178 |
Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil | Q33349723 | ||
Premature atherosclerosis in systemic lupus erythematosus | Q33893354 | ||
Epidemiology of cardiovascular disease in systemic lupus erythematosus | Q33915424 | ||
Systemic lupus erythematosus: a model for atherogenesis? | Q33922220 | ||
Interstitial lung disease in systemic lupus erythematosus | Q34013368 | ||
Treatment of lupus with corticosteroids | Q34226968 | ||
Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus | Q34398069 | ||
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis | Q34961416 | ||
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology | Q35551818 | ||
Lupus nephritis: current issues | Q35553102 | ||
The ACR nomenclature for CNS lupus revisited. | Q35625216 | ||
Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus | Q35625220 | ||
Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials | Q35642238 | ||
Systemic lupus erythematosus trials: successes and issues | Q35864660 | ||
Cerebral inflammation and degeneration in systemic lupus erythematosus | Q35864676 | ||
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action | Q35941069 | ||
Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting | Q35941075 | ||
Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. | Q42166619 | ||
Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematosus with brain involvement by Tc-99m HMPAO brain SPECT. | Q44685474 | ||
Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density | Q45013118 | ||
Mortality and causes of death in systemic lupus erythematosus. | Q45986924 | ||
Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus | Q48599424 | ||
Predicting infection in hospitalized patients with systemic lupus erythematosus | Q71732178 | ||
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation | Q73115074 | ||
Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine | Q73807073 | ||
Damage in systemic lupus erythematosus and its association with corticosteroids | Q74175875 | ||
A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited | Q74552357 | ||
Systemic lupus erythematosus and acute pancreatitis: a case series | Q79827674 | ||
Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus | Q80502363 | ||
P433 | issue | 3 | |
P1104 | number of pages | 8 | |
P304 | page(s) | 162-169 | |
P577 | publication date | 2005-04-01 | |
P1433 | published in | Zeitschrift fuer Rheumatologie | Q15763293 |
P1476 | title | [Glucocorticoid therapy in collagen diseases diseases] | |
P478 | volume | 64 |
Q34648235 | A comparative effectiveness study of bone density changes in women over 40 following three bone health plans containing variations of the same novel plant-sourced calcium | cites work | P2860 |
Search more.